N02CC06 eletriptan

NERVOUS SYSTEM ›ANALGESICS ›ANTIMIGRAINE PREPARATIONS ›Selective serotonin (5HT1) agonists

非健保收載 TFDA 在效許可證 1 FDA 已核准

台灣藥品與外觀

台灣食藥署在效西藥許可證 1 張；以下列出 1 個品項。

無外觀照
"永信"依來曲普坦氫溴酸鹽
仿單 外盒

資料來源：食藥署「西藥許可證」＋「藥品 ATC 碼」＋「藥品外觀」＋「藥品仿單或外盒」開放資料。外觀照與仿單連結指向食藥署原始檔。

適應症

台灣 TFDA 核准適應症

  1. 偏頭痛藥物。

美國 FDA 適應症（英文原文對照）

美國 FDA 核准成分 eletriptan hydrobromide （商品名 Eletriptan HBR / eletriptan hydrobromide） · 仿單更新 2025-01-22

1 INDICATIONS AND USAGE Eletriptan hydrobromide tablets are indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use: Use only if a clear diagnosis of migraine has been established. If a patient has no response to the first migraine attack treated with eletriptan hydrobromide tablets, reconsider the diagnosis of migraine before eletriptan hydrobromide tablets are administered to treat any subsequent attacks. Eletriptan hydrobromide tablets are not intended for the prevention of migraine attacks. Safety and effectiveness of eletriptan hydrobromide tablets have not been established for cluster headache. Eletriptan hydrobromide tablets is a serotonin (5-HT 1B/1D ) receptor agonist (triptan) indicated for the acute treatment of migraine with or without aura in adults ( 1 ) Limitations of Use: Use only after a clear diagnosis of migraine has been established ( 1 ) Not indicated for the prophylactic therapy of migraine ( 1 ) Not indicated for the treatment of cluster headache ( 1 )

資料來源：食藥署西藥許可證適應症（中文）、openFDA US SPL（英文，僅供對照）。

健保給付規定

查無健保特殊給付規定條款；本藥品依一般健保藥品支付規定給付。

實證補充

本藥品尚無實證補充整理（未來新增 Review／指引知識時補列）。

台灣藥品與適應症：食藥署西藥許可證＋ATC＋外觀＋仿單開放資料 · FDA：openFDA US SPL · 健保給付：健保署「全民健康保險藥品給付規定」（更新日 2026-06-09）· 實證補充：人工彙整。 本頁為資訊整理，實際給付與適應症以主管機關公告為準。